First treatment option indicated for CKD in Scotland for 20 years

Pharma Times

10 May 2022 - NICE recommendation for Forxiga could entitle 53,000 adults to the new kidney disease therapy

AstraZeneca today announced that Forxiga (dapagliflozin) has been accepted for restricted use within NHS Scotland by the Scottish Medicines Consortium.

Read Pharma Times article

Michael Wonder

Posted by:

Michael Wonder